NCT07443826: CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 12 planned
- Started
- 1 Jun 2026
- Primary completion
- 30 Sep 2027
- Arms
- Combination: AAV-Follistatin + VEGF Plasmid
- Results
- None posted
- 2 Mar 2026: Trial registered
- 1 Jun 2026: Trial started